Bafisontamab vs Pamvatamig
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR x c-MET · full Non-Small Cell Lung Cancer pipeline
Bafisontamab
Developed by Shanghai EpimAb Biotherapeutics
NCT03797391 · Phase 1/2 · status unknown
This was an open-label, non-randomized, single-arm dose-escalation and expansion study of EMB-01 in patients with advanced solid tumors, with no control group, so it cannot reliably show the drug's effect versus no treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Maximum tolerated dose (MTD) (phase 1 only) (cycle 1 (1cycle = 28 days)); Adverse Events (AEs), and Serious Adverse Events (SAEs) (Screening up to follow-up (30 days after the last dose)); Overall Response Rate (ORR) (phase 2 only) (From the date fo dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months): Phase I dose-escalation/expansion of EMB-01 (EGFR/cMET bispecific): 2 patients had a partial response (1 confirmed) and 14 had stable disease as best response; disease control rate 42.1%. 1600mg QW was determined as the RP2D (recommended phase 2 dose). (mixed)
Result source: NCT03797391
Pamvatamig
Developed by Genmab and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2028 · NCT06885840 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bafisontamab | Pamvatamig |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- Bafisontamab
- —Not reported
- Pamvatamig
- —Not reported
OS, median
- Bafisontamab
- —Not reported
- Pamvatamig
- —Not reported
ORR
- Bafisontamab
- —Not reported
- Pamvatamig
- —Not reported
Duration of response, median
- Bafisontamab
- —Not reported
- Pamvatamig
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Bafisontamab: no structured comparison results are available for Non-Small Cell Lung Cancer.
Pamvatamig: no structured comparison results are available for Non-Small Cell Lung Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bafisontamab's landscape · Pamvatamig's landscape